Here are four highlights:
1. Dr. Landis brings more than 30 years of pharmaceutical research and development experience to the position.
2. He will serve on the board’s science committee.
3. Dr. Landis was most recently Bioanalytical Systems’ board chairman.
4. EyePoint is planning the commercial launches of two ophthalmic products in 2019.
“I look forward to guiding the company as it executes on its strategic and commercial corporate goals in support of the transition to a commercial-stage specialty pharmaceutical company with a pipeline of innovative products for ocular diseases,” Dr. Landis said.
More articles on supply chain:
3 ways ASCs can manage physician preferences
ASC supply chain tip of the day: Collaborate with sales reps
Inventory variability can jeopardize finances — Here’s how you can minimize it
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
